PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 5, 2026Cancer Research0 citations

Abstract 7156: Inhibition in the proliferation of pediatric glioblastoma facilitated with atypical protein kinase c inhibitors

View Full Paper
SRShreejana RimalGTGrazielly Caroline TeodoroGKGaurab Raj Khanal

Key Points

  • The study aims to investigate the effects of atypical protein kinase C inhibitors on pediatric glioblastoma cell proliferation.
  • Investigation of ICA-1S and ζ-Stat on SF188 cells
  • Cells treated with varying inhibitor concentrations for three days
  • Viability assessed to create a dose-response curve
  • Protein expression analyzed via SDS-PAGE and Western blot
  • Evaluation of apoptotic markers in drug-treated cells
  • ICA-1S maximally inhibited proliferation at 75 μM
  • ζ-Stat reduced proliferation by approximately 50% at 20 μM
  • Downregulation of PKC-ι and PKC-ζ protein expression was observed
  • Decreased caspase-3 expression suggests apoptosis activation
  • Findings indicate aPKC inhibition suppresses growth and induces cell death in glioblastoma cells

Abstract

Abstract Pediatric glioblastoma (pGBM) is an aggressive brain tumor with a five-year survival rate of approximately 5%. Current therapeutic options are limited, primarily due to poor blood-brain barrier penetration of available drugs. Atypical Protein Kinase C (aPKC) isoforms, Protein Kinase C- iota (PKC-ι) and Protein Kinase C- zeta (PKC-ζ), play crucial roles in tumor cell proliferation and survival. In this study, we investigated the effects of ICA-1S 5-amino-1-((1R,2S,3S,4R)-2,3-dihydroxy-4-methylcyclopentyl)-1H-imidazole-4-carboxamide, a selective PKC-ι inhibitor, and ζ-Stat 8-hydroxy-1,3,6-naphthalenetrisulfonic acid, a PKC-ζ inhibitor, on pediatric glioblastoma SF188 cells. SF188 cells (50,000/well) were seeded in 6-well plates and treated with varying concentrations of ICA-1S and ζ-Stat for three days. On the fourth day, cell viability was determined to generate a dose-response curve. ICA-1S showed maximal inhibition at 75 μM, while ζ-Stat decreased proliferation by approximately 50% at 20 μM. These results suggest that both PKC-ι and PKC-ζ contribute to SF188 cell proliferation. To explore the molecular mechanisms underlying this inhibition, protein lysates from treated and untreated cells were analyzed via Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) and Western blotting. Both ICA-1S and ζ-Stat treatments resulted in downregulation of PKC-ι and PKC-ζ protein expression compared to control samples. Furthermore, expression of the apoptotic marker Caspase-3 was found to be decreased in drug-treated cells, suggesting activation of apoptotic signaling following inhibition of aPKCs. These findings indicate that selective inhibition of aPKCs suppresses proliferation and induces apoptosis in pediatric glioblastoma cells. Ongoing and future studies will employ immunoprecipitation, immunofluorescence, and WST assays to elucidate downstream signaling pathways and validate ICA-1S and ζ-Stat as potential therapeutic candidates for pediatric glioblastoma. Citation Format: Shreejana Rimal, Grazielly Teodoro, Gaurab Raj Khanal, Mildred Acevedo-Duncan. Inhibition in the proliferation of pediatric glioblastoma facilitated with atypical protein kinase c inhibitors abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 7156.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Rimal et al. (2026) studied this question.

synapsesocial.com/papers/69d1fdd4a79560c99a0a422ahttps://doi.org/10.1158/1538-7445.am2026-7156
Ask AI
Helpful
Bookmark
Share
View Full Paper